Answers are grounded in this paper and cite their sources.
Background and objective Trofinetide is the first approved treatment for Rett syndrome, a rare, neurodevelopmental disorder associated with an increased risk of QT interval prolongation. This phase 1 study was primarily designed to evaluate electrocardiogram (ECG) parameters including Fridericia’s heart rate–corrected QT interval (QTcF) and its relationship with trofinetide blood concentration (C-QTcF) at therapeutic (12 g) and supratherapeutic trofinetide doses in healthy adults.Methods Using a nested crossover design, 40 participants received one treatment in each of five dosing periods: Periods 1 and 5 – oral moxifloxacin 400 mg (positive control) or matching placebo; and Periods 2 to 4 – single oral doses of trofinetide (12 g, 18 g, and 24 g) or matching placebo. Using concentration-QTc modeling, the primary ECG endpoint was the change from time-matched baseline in QTcF (ΔQTcF) with trofinetide blood concentrations. The threshold of concern for cardiac repolarization is ≥10 ms for the upper bounds of the two-sided 90% confidence interval of the predicted mean placebo-adjusted ΔQTcF (ΔΔQTcF).Results At the highest exposures (maximum drug concentration) for each trofinetide dose, the upper 90% two-sided confidence bound for ΔΔQTcF was below 10 ms.Conclusions Therapeutic or supratherapeutic trofinetide doses were not associated with significant QTcF prolongation.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: